Find Dalteparin sodium manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

EU WC

0

NDC API

0

VMF

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

USP

0

JP

FDF DossiersDRUG PRODUCT COMPOSITIONS

6RELATED EXCIPIENT COMPANIES

7EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API/FDF Prices: Book a Demo

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

Annual Reports

NA

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as:
Molecular Formula
C12H17NO20S3-4
Molecular Weight
591.5  g/mol
InChI Key
OHJKXVLJWUPWQG-IUYNYSEKSA-J

Dalteparin sodium
1 2D Structure

Dalteparin sodium

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate
2.1.2 InChI
InChI=1S/C12H21NO20S3/c14-4-3(13-34(20,21)22)11(19)30-2(1-29-35(23,24)25)7(4)31-12-9(33-36(26,27)28)6(16)5(15)8(32-12)10(17)18/h2-9,11-16,19H,1H2,(H,17,18)(H,20,21,22)(H,23,24,25)(H,26,27,28)/p-4/t2-,3?,4-,5?,6+,7?,8?,9?,11?,12-/m1/s1
2.1.3 InChI Key
OHJKXVLJWUPWQG-IUYNYSEKSA-J
2.1.4 Canonical SMILES
C(C1C(C(C(C(O1)O)NS(=O)(=O)[O-])O)OC2C(C(C(C(O2)C(=O)[O-])O)O)OS(=O)(=O)[O-])OS(=O)(=O)[O-]
2.1.5 Isomeric SMILES
C([C@@H]1C([C@@H](C(C(O1)O)NS(=O)(=O)[O-])O)O[C@H]2C([C@H](C(C(O2)C(=O)[O-])O)O)OS(=O)(=O)[O-])OS(=O)(=O)[O-]
2.2 Create Date
2009-05-14
3 Chemical and Physical Properties
Molecular Weight 591.5 g/mol
Molecular Formula C12H17NO20S3-4
XLogP3-5.6
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count21
Rotatable Bond Count6
Exact Mass590.95060545 g/mol
Monoisotopic Mass590.95060545 g/mol
Topological Polar Surface Area376 Ų
Heavy Atom Count36
Formal Charge-4
Complexity1040
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count6
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 4  
Drug NameHeparin sodium in plastic container
Active IngredientHeparin sodium
Dosage FormInjectable
RouteInjection
Strength10,000 units/ml; 5,000 units/ml; 20,000 units/ml; 1,000 units/ml
Market StatusPrescription
CompanyFresenius Kabi Usa

2 of 4  
Drug NameHeparin sodium preservative free
Active IngredientHeparin sodium
Dosage FormInjectable
RouteInjection
Strength10,000 units/ml; 1,000 units/ml
Market StatusPrescription
CompanyHospira; Shenzhen Techdow; Pfizer; Fresenius Kabi Usa; Sagent Pharms

3 of 4  
Drug NameHeparin sodium in plastic container
Active IngredientHeparin sodium
Dosage FormInjectable
RouteInjection
Strength10,000 units/ml; 5,000 units/ml; 20,000 units/ml; 1,000 units/ml
Market StatusPrescription
CompanyFresenius Kabi Usa

4 of 4  
Drug NameHeparin sodium preservative free
Active IngredientHeparin sodium
Dosage FormInjectable
RouteInjection
Strength10,000 units/ml; 1,000 units/ml
Market StatusPrescription
CompanyHospira; Shenzhen Techdow; Pfizer; Fresenius Kabi Usa; Sagent Pharms

Drugs in Development

read-more
read-more
  • Development Update

Details:

Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.


Lead Product(s): Dalteparin sodium,Inapplicable

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Leo Pharma

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 23, 2022

blank

01

Galician Research Group on Digestive Tumors

Country
arrow
Arab Health
Not Confirmed

Galician Research Group on Digestive Tumors

Country
arrow
Arab Health
Not Confirmed

Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 23, 2022

blank
  • Development Update

Details:

Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.


Lead Product(s): Dalteparin sodium,Inapplicable

Therapeutic Area: Hematology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: Leo Pharma | Sunnybrook Research Institute

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 12, 2021

blank

02

Sunnybrook Health Sciences Centre

Country
arrow
Arab Health
Not Confirmed

Sunnybrook Health Sciences Centre

Country
arrow
Arab Health
Not Confirmed

Lead Product(s) : Dalteparin sodium,Inapplicable

Therapeutic Area : Hematology

Highest Development Status : Phase IV

Partner/Sponsor/Collaborator : Leo Pharma | Sunnybrook Research Institute

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 12, 2021

blank
  • Development Update

Details:

Innohep (Tinzaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia.


Lead Product(s): Dalteparin sodium,Inapplicable

Therapeutic Area: Hematology Brand Name: Innohep

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Leo Pharma

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 20, 2015

blank

03

Assistance Publique – Hôpitaux de Paris

Country
arrow
Arab Health
Not Confirmed

Assistance Publique – Hôpitaux de Paris

Country
arrow
Arab Health
Not Confirmed

Details : Innohep (Tinzaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia.

Product Name : Innohep

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 20, 2015

blank
  • Development Update

Details:

Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.


Lead Product(s): Dalteparin sodium,Inapplicable

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Leo Pharma

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 09, 2014

blank

04

Centre Hospitalier Universitaire de Saint Etienne

Country
arrow
Arab Health
Not Confirmed

Centre Hospitalier Universitaire de Saint Etienne

Country
arrow
Arab Health
Not Confirmed

Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 09, 2014

blank

Details:

Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Failure, Chronic.


Lead Product(s): Dalteparin sodium,Inapplicable

Therapeutic Area: Nephrology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: Christine Ribic

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 28, 2013

blank

05

Leo Pharma

Denmark
arrow
Arab Health
Not Confirmed

Leo Pharma

Denmark
arrow
Arab Health
Not Confirmed

Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Failure, Chronic.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 28, 2013

blank

Details:

Bemiparin Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Venous Thrombosis.


Lead Product(s): Dalteparin sodium,Inapplicable

Therapeutic Area: Hematology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 18, 2013

blank

06

Berlin Chemie

Germany
arrow
Arab Health
Not Confirmed

Berlin Chemie

Germany
arrow
Arab Health
Not Confirmed

Details : Bemiparin Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Venous Thrombosis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 18, 2013

blank

Details:

Fragmin (Dalteparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Kidney Failure, Chronic.


Lead Product(s): Dalteparin sodium,Inapplicable

Therapeutic Area: Nephrology Brand Name: Fragmin

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 18, 2013

blank

07

Pfizer Inc

U.S.A
arrow
Arab Health
Not Confirmed

Pfizer Inc

U.S.A
arrow
Arab Health
Not Confirmed

Details : Fragmin (Dalteparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Kidney Failure, Chronic.

Product Name : Fragmin

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 18, 2013

blank
  • Development Update

Details:

Nadroparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.


Lead Product(s): Dalteparin sodium,Enoxaparin Sodium,Tedelparin

Therapeutic Area: Hematology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 11, 2013

blank

08

Academisch Medisch Centrum - Universiteit van Amsterdam

Country
arrow
Arab Health
Not Confirmed

Academisch Medisch Centrum - Universiteit van Amsterdam

Country
arrow
Arab Health
Not Confirmed

Lead Product(s) : Dalteparin sodium,Enoxaparin Sodium,Tedelparin

Therapeutic Area : Hematology

Highest Development Status : Phase IV

Partner/Sponsor/Collaborator : Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Nadroparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 11, 2013

blank
  • Development Update

Details:

Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fetal Growth Retardation.


Lead Product(s): Dalteparin sodium,Inapplicable

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: Aarhus University Hospital | Leo Pharma

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 08, 2011

blank

09

University of Aarhus

Country
arrow
Arab Health
Not Confirmed

University of Aarhus

Country
arrow
Arab Health
Not Confirmed

Lead Product(s) : Dalteparin sodium,Inapplicable

Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

Highest Development Status : Phase IV

Partner/Sponsor/Collaborator : Aarhus University Hospital | Leo Pharma

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fetal Growth Retardation.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 08, 2011

blank

Details:

Innohep (Tinzaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Venous Thromboembolism.


Lead Product(s): Dalteparin sodium,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Innohep

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 25, 2010

blank

10

Leo Pharma

Denmark
arrow
Arab Health
Not Confirmed

Leo Pharma

Denmark
arrow
Arab Health
Not Confirmed

Details : Innohep (Tinzaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Venous Thromboembolism.

Product Name : Innohep

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 25, 2010

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Aspen API

Netherlands
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAspen API. More than just an API™

Flag Netherlands
Digital Content Digital Content

Regulatory Info : Cancelled

Registration Country : Spain

Nadroparin Calcium

Brand Name : Fraxiparine Forte

Dosage Form : Injectable Solution

Dosage Strength :

Packaging :

Approval Date : 28-11-2000

Application Number : 63496

Regulatory Info : Cancelled

Registration Country : Spain

Aspen API Comapny Banner

02

Aspen API

Netherlands
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAspen API. More than just an API™

Flag Netherlands
Digital Content Digital Content

Regulatory Info : Cancelled

Registration Country : Spain

Nadroparin Calcium

Brand Name : Fraxiparine

Dosage Form : Injectable Solution

Dosage Strength :

Packaging :

Approval Date : 01-04-1998

Application Number : 61783

Regulatory Info : Cancelled

Registration Country : Spain

Aspen API Comapny Banner

03

Aspen API

Netherlands
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAspen API. More than just an API™

Flag Netherlands
Digital Content Digital Content

Regulatory Info : Cancelled

Registration Country : Spain

Nadroparin Calcium

Brand Name : Fraxiparine Forte

Dosage Form : Injectable Solution

Dosage Strength :

Packaging :

Approval Date : 28-11-2000

Application Number : 63498

Regulatory Info : Cancelled

Registration Country : Spain

Aspen API Comapny Banner

04

Aspen API

Netherlands
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAspen API. More than just an API™

Flag Netherlands
Digital Content Digital Content

Regulatory Info : Cancelled

Registration Country : Spain

Nadroparin Calcium

Brand Name : Fraxiparine

Dosage Form : Injectable Solution

Dosage Strength :

Packaging :

Approval Date : 01-06-1991

Application Number : 58983

Regulatory Info : Cancelled

Registration Country : Spain

Aspen API Comapny Banner

05

Aspen API

Netherlands
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAspen API. More than just an API™

Flag Netherlands
Digital Content Digital Content

Regulatory Info : Cancelled

Registration Country : Spain

Nadroparin Calcium

Brand Name : Fraxiparine

Dosage Form : Injectable Solution

Dosage Strength :

Packaging :

Approval Date : 01-11-1989

Application Number : 58496

Regulatory Info : Cancelled

Registration Country : Spain

Aspen API Comapny Banner

06

Aspen API

Netherlands
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAspen API. More than just an API™

Flag Netherlands
Digital Content Digital Content

Regulatory Info : Cancelled

Registration Country : Spain

Nadroparin Calcium

Brand Name : Fraxiparine Forte

Dosage Form : Injectable Solution

Dosage Strength :

Packaging :

Approval Date : 28-11-2000

Application Number : 63497

Regulatory Info : Cancelled

Registration Country : Spain

Aspen API Comapny Banner

07

Aspen API

Netherlands
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAspen API. More than just an API™

Flag Netherlands
Digital Content Digital Content

Regulatory Info : Cancelled

Registration Country : Spain

Nadroparin Calcium

Brand Name : Fraxiparine

Dosage Form : Injectable Solution

Dosage Strength :

Packaging :

Approval Date : 01-06-1991

Application Number : 58982

Regulatory Info : Cancelled

Registration Country : Spain

Aspen API Comapny Banner

08

Aspen API

Netherlands
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAspen API. More than just an API™

Flag Netherlands
Digital Content Digital Content

Regulatory Info : Cancelled

Registration Country : Spain

Nadroparin Calcium

Brand Name : Fraxiparine

Dosage Form : Injectable Solution

Dosage Strength : 9500IU

Packaging :

Approval Date : 02-06-2021

Application Number : 86000

Regulatory Info : Cancelled

Registration Country : Spain

Aspen API Comapny Banner

09

Nadroparin

Brand Name : Fraxiparine 0.8ml

Dosage Form : INJ

Dosage Strength : 7600iu/0.8ml

Packaging : 0.8X10iu/0.8ml

Approval Date :

Application Number :

Regulatory Info : Originator

Registration Country : South Africa

Aspen API Comapny Banner

10

Nadroparin

Brand Name : Fraxiparine 1.0ml

Dosage Form : INJ

Dosage Strength : 9500iu/1ml

Packaging : 1X10iu/1ml

Approval Date :

Application Number :

Regulatory Info : Originator

Registration Country : South Africa

Aspen API Comapny Banner
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - INJECTABLE;SUBCUTANEOUS - 10,000IU/M...DOSAGE - INJECTABLE;SUBCUTANEOUS - 10,000IU/ML (10,000IU/ML)

USFDA APPLICATION NUMBER - 20287

read-more

DOSAGE - INJECTABLE;SUBCUTANEOUS - 10,000IU/4...DOSAGE - INJECTABLE;SUBCUTANEOUS - 10,000IU/4ML (2,500IU/ML)

USFDA APPLICATION NUMBER - 20287

read-more

DOSAGE - INJECTABLE;SUBCUTANEOUS - 12,500IU/0...DOSAGE - INJECTABLE;SUBCUTANEOUS - 12,500IU/0.5ML (25,000IU/ML)

USFDA APPLICATION NUMBER - 20287

read-more

DOSAGE - INJECTABLE;SUBCUTANEOUS - 15,000IU/0...DOSAGE - INJECTABLE;SUBCUTANEOUS - 15,000IU/0.6ML (25,000IU/ML)

USFDA APPLICATION NUMBER - 20287

read-more

DOSAGE - INJECTABLE;SUBCUTANEOUS - 18,000IU/0...DOSAGE - INJECTABLE;SUBCUTANEOUS - 18,000IU/0.72ML (25,000IU/ML)

USFDA APPLICATION NUMBER - 20287

read-more

DOSAGE - INJECTABLE;SUBCUTANEOUS - 2,500IU/0....DOSAGE - INJECTABLE;SUBCUTANEOUS - 2,500IU/0.2ML (12,500IU/ML)

USFDA APPLICATION NUMBER - 20287

read-more

DOSAGE - INJECTABLE;SUBCUTANEOUS - 5,000IU/0....DOSAGE - INJECTABLE;SUBCUTANEOUS - 5,000IU/0.2ML (25,000IU/ML)

USFDA APPLICATION NUMBER - 20287

read-more

DOSAGE - INJECTABLE;SUBCUTANEOUS - 7,500IU/0....DOSAGE - INJECTABLE;SUBCUTANEOUS - 7,500IU/0.3ML (25,000IU/ML)

USFDA APPLICATION NUMBER - 20287

read-more

DOSAGE - INJECTABLE;SUBCUTANEOUS - 95,000IU/3...DOSAGE - INJECTABLE;SUBCUTANEOUS - 95,000IU/3.8ML (25,000IU/ML)

USFDA APPLICATION NUMBER - 20287

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Parenteral

read-more
read-more

Topical

read-more
read-more

Solubilizers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for / Dalteparin sodium API manufacturers, exporters & distributors?

Dalteparin sodium manufacturers, exporters & distributors 1

38

PharmaCompass offers a list of Dalteparin sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dalteparin sodium manufacturer or Dalteparin sodium supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dalteparin sodium manufacturer or Dalteparin sodium supplier.

PharmaCompass also assists you with knowing the Dalteparin sodium API Price utilized in the formulation of products. Dalteparin sodium API Price is not always fixed or binding as the Dalteparin sodium Price is obtained through a variety of data sources. The Dalteparin sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Dalteparin sodium

Heparinum natricum Manufacturers

A Heparinum natricum manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Heparinum natricum, including repackagers and relabelers. The FDA regulates Heparinum natricum manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Heparinum natricum API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Heparinum natricum manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Heparinum natricum Suppliers

A Heparinum natricum supplier is an individual or a company that provides Heparinum natricum active pharmaceutical ingredient (API) or Heparinum natricum finished formulations upon request. The Heparinum natricum suppliers may include Heparinum natricum API manufacturers, exporters, distributors and traders.

click here to find a list of Heparinum natricum suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Heparinum natricum USDMF

A Heparinum natricum DMF (Drug Master File) is a document detailing the whole manufacturing process of Heparinum natricum active pharmaceutical ingredient (API) in detail. Different forms of Heparinum natricum DMFs exist exist since differing nations have different regulations, such as Heparinum natricum USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Heparinum natricum DMF submitted to regulatory agencies in the US is known as a USDMF. Heparinum natricum USDMF includes data on Heparinum natricum's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Heparinum natricum USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Heparinum natricum suppliers with USDMF on PharmaCompass.

Heparinum natricum JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Heparinum natricum Drug Master File in Japan (Heparinum natricum JDMF) empowers Heparinum natricum API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Heparinum natricum JDMF during the approval evaluation for pharmaceutical products. At the time of Heparinum natricum JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Heparinum natricum suppliers with JDMF on PharmaCompass.

Heparinum natricum KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Heparinum natricum Drug Master File in Korea (Heparinum natricum KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Heparinum natricum. The MFDS reviews the Heparinum natricum KDMF as part of the drug registration process and uses the information provided in the Heparinum natricum KDMF to evaluate the safety and efficacy of the drug.

After submitting a Heparinum natricum KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Heparinum natricum API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Heparinum natricum suppliers with KDMF on PharmaCompass.

Heparinum natricum GMP

Heparinum natricum Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Heparinum natricum GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Heparinum natricum GMP manufacturer or Heparinum natricum GMP API supplier for your needs.

Heparinum natricum CoA

A Heparinum natricum CoA (Certificate of Analysis) is a formal document that attests to Heparinum natricum's compliance with Heparinum natricum specifications and serves as a tool for batch-level quality control.

Heparinum natricum CoA mostly includes findings from lab analyses of a specific batch. For each Heparinum natricum CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Heparinum natricum may be tested according to a variety of international standards, such as European Pharmacopoeia (Heparinum natricum EP), Heparinum natricum JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Heparinum natricum USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty